Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea flag South Korea · Delayed Price · Currency is KRW
68,300
+100 (0.15%)
At close: Aug 14, 2026

KRX:185750 Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
78,54777,509109,073212,52180,95342,720
Depreciation & Amortization
45,17444,79839,77237,03033,59827,482
Loss (Gain) From Sale of Assets
-402.42-542.27-154-111.88-54.05-119.34
Asset Writedown & Restructuring Costs
76.9380.82985.36199.794,008-
Loss (Gain) From Sale of Investments
-629.27-747.232,764-1,4652,77298.87
Loss (Gain) on Equity Investments
----798.36460.38603.47
Provision & Write-off of Bad Debts
8.6-252.25637.26133.39996.56-533.19
Other Operating Activities
13,60814,017-12,19040,96922,30010,345
Change in Accounts Receivable
6,9791,4023,509-20,947-45,316-18,267
Change in Inventory
-76,112-96,566-114,342-5,980-54,466-53,771
Change in Accounts Payable
3,41213,31314,41038,58415,824-15,598
Change in Unearned Revenue
-14.81.8318.551.140.16-
Change in Other Net Operating Assets
15,28514,34619,80618,0246,65819,942
Operating Cash Flow
85,93167,35964,289318,16067,73412,904
Operating Cash Flow Growth
586.60%4.78%-79.79%369.72%424.92%-87.63%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-194,935-140,917-38,474-41,218-44,898-48,243
Sale of Property, Plant & Equipment
553.04555.04243.25451.58142.13142.41
Sale (Purchase) of Intangibles
-48,921-38,215-27,483-27,588-8,166-3,591
Investment in Securities
-52,417-66,78169,268-102,998-12,806-39,332
Other Investing Activities
274.1273.19175.5539.75347.81213.96
Investing Cash Flow
-295,447-245,2843,731-171,313-65,380-90,809

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-217,704100,00032,000-101,596
Long-Term Debt Repaid
--35,157-133,743-58,050-3,213-3,714
Net Debt Issued (Repaid)
182,342182,548-33,743-26,050-3,21397,883
Repurchase of Common Stock
--1,770-16,008-6,025-1,888-1,935
Dividends Paid
-13,824-13,824-13,331-11,609-11,239-10,808
Other Financing Activities
14.0910.02-29.7-16.53--0
Financing Cash Flow
168,533166,964-63,112-43,700-16,34085,139

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
635.34-1,2723,915-917.57-410.12920.1
Net Cash Flow
-40,347-12,2348,824102,229-14,3968,154

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-109,004-73,55825,815276,94222,836-35,339
Free Cash Flow Growth
---90.68%1112.74%--
Free Cash Flow Margin
-6.27%-4.35%1.63%16.59%1.53%-2.63%
Free Cash Flow Per Share
-8188.39-5525.421948.9119821.041696.38-2578.75
Levered Free Cash Flow
-176,750-122,329-75,307169,732-1,365-33,053
Unlevered Free Cash Flow
-172,283-118,142-70,108175,5262,914-30,534

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
6,2216,2327,6558,6316,4443,758
Cash Income Tax Paid
24,44023,78734,86811,81215,56151,688
Change in Working Capital
-50,451-67,504-76,59929,682-77,299-67,694